Skip to main content
SpringerLink
Log in
Book cover

Selective Activation of Drugs by Redox Processes pp 213–222Cite as

Activity of Bioreductive Agents in Human and Rodent Tumor Cells

  • Chapter

Part of the book series: NATO ASI Series ((NSSA,volume 198))

Abstract

It has been well established that oxygen-deficient or hypoxic cells limit the success of radiotherapy in animal tumor models1 and evidence exists to implicate these cells as a cause for local failures in at least some human cancers2. Hypoxic cells may also be refractory to certain conventional anticancer agents3, 4 because (i) these cells may be relatively inaccessible to the drug because they are located in poorly vascularized areas of a tumor, (ii) hypoxia per se may reduce the efficacy of the agent, or (iii) under hypoxic conditions cells may be in a non-cycling state which protects them from cycle specific drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. G.E. Adams, Hypoxic cell sensitizers for radio-therapy, in: Cancer. A comprehensive Treatise, Vol. 6, F.F. Becker, ed., Plenum Publications Inc., New York, 181 (1977).

    Google Scholar 

  2. R.S. Bush, R.D.T. Jenkin, W.E.C. Allt, F.A. Beale, H. Bean, A.J. Derabo and J.F. Pringle, Definitive evidence for hypoxic cells influencing cure in cancer therapy, Br. J. Cancer. 37:302 (1978).

    Google Scholar 

  3. D.W. Sieraann, Modification of chemotherapy by nitroiraidazoles, Int. J. Radiat. Oncol. Biol. Phys. 10:1585 (1984).

    Article  Google Scholar 

  4. A.C. Sartorelli, The role of mitomycin antibiotics in the chemotherapy of solid tumors, Biochem. Pharmacol. 35:67 (1986).

    Article  PubMed  CAS  Google Scholar 

  5. G.E. Adams and I.J. Stratford, Hypoxia-mediated nitroheterocyclic drugs in the radio- and chemotherapy of cancer, Biochem. Pharmacol. 35:71 (1986).

    Article  PubMed  CAS  Google Scholar 

  6. E.M. Zeman, J.M. Brown, D. Phil, M.J. Lemmon, V.K. Hirst, and W.W. Lee, SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells, Int. J. Radiat. Oncol. Biol. Phys. 12:1239 (1986).

    Article  PubMed  CAS  Google Scholar 

  7. J.M. Brown, On the mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles, Int. J. Radiat. Oncol. Biol. Phys. 8:675 (1982).

    Article  PubMed  CAS  Google Scholar 

  8. N. McNally, Enhancement of chemotherapy, Int. J. Radiât. Oncol. Biol. Phys. 8:593 (1982).

    Article  PubMed  CAS  Google Scholar 

  9. D.W. Siemann, Potentiation of chemotherapy by hypoxic cell radiation sensitizers — a review, Int. J. Radiat. Oncol. Biol. Phys. 8:1029 (1982).

    Article  PubMed  CAS  Google Scholar 

  10. D.J. Chaplin, Hypoxia-targetted chemotherapy: a role for vasoactive drugs, Radiat. Res. 2:731 (1987).

    Google Scholar 

  11. J.M. Brown, Exploitation of bioreductive agents with vasoactive drugs, Radiat. Res. 2:719 (1987).

    Google Scholar 

  12. I.J. Stratford, J. Godden, N. Howells, P. Embling, and G.E. Adams, Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours, Radiat. Res. 2:737 (1987).

    Google Scholar 

  13. W.G. DeGraff, M.S. Russo, J. Gamson, and J. Mitchell, Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione, Int. J. Radiat. Oncol. Biol. Phys. 16:1021 (1989).

    Article  PubMed  CAS  Google Scholar 

  14. E.M. Zeman, J.C. Kuruppu, K.A. Biedermann, and J.M. Brown, Hypoxic cytotoxicity and radiosensitization by SR-4233: a comparison between rodent and human cell lines, 15th L.H. Gray Conference, Canterbury, England (Abstract,1989).

    Google Scholar 

  15. J.M. Brown and J.C. Kuruppu, Differences between the hypoxic cytotoxicity of bioreductive drugs towards human and rodent cells, 15th L.H. Gray Conference, Canterbury, England (Abstract, 1989).

    Google Scholar 

  16. D.W. Siemann, E.M. Lord, P.C. Keng, and K.T. Wheeler, Cell sub populations dispersed from solid tumours and separated by centrifugal elutriation, Br. J. Cancer 44:100 (1981).

    Article  PubMed  CAS  Google Scholar 

  17. D.W. Siemann, Do in vitro studies of potential lethal damage repair predict for in situ results?, Int. J. Radiat. Biol. in press (1989).

    Google Scholar 

  18. G.E. Adams, I. Ahmed, P.W. Sheldon, and I.J. Stratford, Radiation sensitization and chemopotentiation: RSU 1069 a compound more efficient than misonidazole in vitro and in vivo, Br. J. Cancer. 49:571 (1984).

    Article  PubMed  CAS  Google Scholar 

  19. D.W. Siemann, K. Maddison, and K. Wolf, Potentiation of melphalan in the KHT sarcoma by the radiosensitizer RSU 1069, Int. J. Radiat. Oncol. Biol. Phys. 10:1657 (1984).

    Article  PubMed  CAS  Google Scholar 

  20. D.W. Siemann, K. Alliet, and K. Wolf, Enhancement of the antitumour efficacy of Lomustine by the radiosensitizer RSU 1069, Cancer Treat. Rep. 69:1409 (1985).

    PubMed  CAS  Google Scholar 

  21. I. Ahmed, T.C. Jenkins, J.M. Walling, I.J. Stratford, P.W. Sheldon, G.E. Adaras, and E.M. Fielden, Analogues of RSU 1069: Radiosensitization and toxicity in vitro and in vivo, Int. J. Radiat. Oncol. Biol. Phys. 12:1079 (1986).

    Article  PubMed  CAS  Google Scholar 

  22. E.J. Hall, Radiobiology for the Radiologist, J. B. Lippincott Co., Philadelphia. (1988).

    Google Scholar 

  23. J.E. Biaglow, M.E. Varnes, E.P. Clark, and E.P. Epp, The role of thiols in cellular response to radiation and drugs, Radiat. Res. 95:437 (1983).

    Article  PubMed  CAS  Google Scholar 

  24. T.C. Hamilton, M.A. Winkes, K.G. Louie, G. Batist, B.C. Behrens, T. Tsuruo, K.R. Grotzinger, W.M. McKoy, R.C. Young, and R.F. Ozols, Augumentation of Adriamycin, Melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathionine depletion, Biochem. Pharmacol., 34:2583 (1985).

    Article  PubMed  CAS  Google Scholar 

  25. F.Y.F. Lee, A.R. Vessey, and D.W. Siemann, Glutathione as a determinant of cellular response to Doxorubicin, Nat. Cancer Inst. Monogr. 6:211 (1988).

    Google Scholar 

  26. F.Y.F. Lee, D.W. Siemann, and R.M. Sutherland, Changes in cellular glutathione content during Adriamycin treatment in human ovarian cancer — a possible indicator of chemosensitivity, Br. J. Cancer. 60:291 (1989).

    Article  PubMed  CAS  Google Scholar 

  27. J.B. Mitchell, T.L. Phillips, W. DeGraff, J. Carmichael, R.K. Rajpal, and A. Russo, The relationship of SR-2508 sensitizer enhancement ratio to cellular glutathione levels in human tumor cell lines, Int. J. Radiat. Oncol. Biol. Phys. 12:1143 (1986).

    Article  PubMed  CAS  Google Scholar 

  28. G. Morstyn, A. Russo, D. Carney, E. Karawa, S.H. Wilson, and J.B. Mitchell, Heterogeneity in the radiation survival curves and the biochemical properties of human lung cancer cell lines, J. Natl. Cancer Int. 73:801 (1984).

    CAS  Google Scholar 

  29. M.J. Allalunis-Turner, F.Y.F. Lee, and D.W. Siemann, Comparison of glutathione levels in rodent and human tumor cells grown in vitro and in vivo. Cancer Research 48:3657 (1988).

    PubMed  CAS  Google Scholar 

  30. M.I. Walton, C.R. Wolf, and P. Workman, Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins, Int. J. Radiat. Oncol. Biol. Phys. 16:983 (1989).

    Article  PubMed  CAS  Google Scholar 

  31. J. Midander, P. Deschavanne, E.P. Malaise, and L. Revesz, Survival curves of irradiated glutathione-deficient human fibroblasts: indication of a reduced enhancement of radiosensitivity by oxygen and misonidazole, Int. J. Radiat. Oncol. Biol. Phys. 8:443 (1982).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics Division, University of Rochester Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, New York, 14642, USA

    Dietmar W. Siemann

Authors
  1. Dietmar W. Siemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MRC Radiobiology Unit, Didcot, Chilton, Oxon., OX11 ORD, UK

    G. E. Adams  & E. M. Fielden  & 

  2. Facoltà di Farmacia, Istituto di Scienze Chimiche, Università Degli Studi di Bologna, 40127, Bologna, Via S. Donato, 15, Italy

    A. Breccia

  3. CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK

    P. Wardman

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Siemann, D.W. (1990). Activity of Bioreductive Agents in Human and Rodent Tumor Cells. In: Adams, G.E., Breccia, A., Fielden, E.M., Wardman, P. (eds) Selective Activation of Drugs by Redox Processes. NATO ASI Series, vol 198. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3768-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3768-7_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6679-9

  • Online ISBN: 978-1-4615-3768-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation